Cargando…
Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study
OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients wit...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Korean College of Neuropsychopharmacology
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329105/ https://www.ncbi.nlm.nih.gov/pubmed/35879041 http://dx.doi.org/10.9758/cpn.2022.20.3.567 |
_version_ | 1784757866308042752 |
---|---|
author | Woo, Young Sup Park, Sung-Yong Yoon, Bo-Hyun Choi, Won-Seok Wang, Sheng-Min Bahk, Won-Myong |
author_facet | Woo, Young Sup Park, Sung-Yong Yoon, Bo-Hyun Choi, Won-Seok Wang, Sheng-Min Bahk, Won-Myong |
author_sort | Woo, Young Sup |
collection | PubMed |
description | OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients with schizophrenia who were partially or completely unresponsive to treatment with OLA monotherapy. Eligible subjects were randomly assigned at a 11 ratio to continuation of OLA monotherapy (OLA group) or OLA with AMI augmentation (AMI group). Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at 1, 2, and 4 weeks. RESULTS: The changes in PANSS total score and PANSS-positive subscale score were significantly different (p < 0.05) between the OLA and AMI groups. The differences between the two groups in PANSS-negative subscale, PANSS-general subscale, Brief Psychiatric Rating Scale, and Clinical Global Impression-Severity (CGI-S) scale scores were not statistically significant. CONCLUSION: AMI augmentation could be an effective strategy for patients with schizophrenia who show inadequate early response to OLA monotherapy. |
format | Online Article Text |
id | pubmed-9329105 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Korean College of Neuropsychopharmacology |
record_format | MEDLINE/PubMed |
spelling | pubmed-93291052022-08-31 Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study Woo, Young Sup Park, Sung-Yong Yoon, Bo-Hyun Choi, Won-Seok Wang, Sheng-Min Bahk, Won-Myong Clin Psychopharmacol Neurosci Brief Report OBJECTIVE: The purpose of this study was to compare the efficacy and tolerability of continued olanzapine (OLA) versus amisulpride (AMI) augmentation in schizophrenic patients with poor response to OLA monotherapy. METHODS: The present 4-week, randomized, rater-blinded study included 25 patients with schizophrenia who were partially or completely unresponsive to treatment with OLA monotherapy. Eligible subjects were randomly assigned at a 11 ratio to continuation of OLA monotherapy (OLA group) or OLA with AMI augmentation (AMI group). Efficacy was primarily evaluated using the Positive and Negative Syndrome Scale (PANSS) at baseline and at 1, 2, and 4 weeks. RESULTS: The changes in PANSS total score and PANSS-positive subscale score were significantly different (p < 0.05) between the OLA and AMI groups. The differences between the two groups in PANSS-negative subscale, PANSS-general subscale, Brief Psychiatric Rating Scale, and Clinical Global Impression-Severity (CGI-S) scale scores were not statistically significant. CONCLUSION: AMI augmentation could be an effective strategy for patients with schizophrenia who show inadequate early response to OLA monotherapy. Korean College of Neuropsychopharmacology 2022-08-31 2022-08-31 /pmc/articles/PMC9329105/ /pubmed/35879041 http://dx.doi.org/10.9758/cpn.2022.20.3.567 Text en Copyright© 2022, Korean College of Neuropsychopharmacology https://creativecommons.org/licenses/by-nc/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0 (https://creativecommons.org/licenses/by-nc/4.0/) ) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Brief Report Woo, Young Sup Park, Sung-Yong Yoon, Bo-Hyun Choi, Won-Seok Wang, Sheng-Min Bahk, Won-Myong Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study |
title | Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study |
title_full | Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study |
title_fullStr | Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study |
title_full_unstemmed | Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study |
title_short | Amisulpride Augmentation in Schizophrenia Patients with Poor Response to Olanzapine: A 4-week, Randomized, Rater-Blind, Controlled, Pilot Study |
title_sort | amisulpride augmentation in schizophrenia patients with poor response to olanzapine: a 4-week, randomized, rater-blind, controlled, pilot study |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9329105/ https://www.ncbi.nlm.nih.gov/pubmed/35879041 http://dx.doi.org/10.9758/cpn.2022.20.3.567 |
work_keys_str_mv | AT wooyoungsup amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy AT parksungyong amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy AT yoonbohyun amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy AT choiwonseok amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy AT wangshengmin amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy AT bahkwonmyong amisulprideaugmentationinschizophreniapatientswithpoorresponsetoolanzapinea4weekrandomizedraterblindcontrolledpilotstudy |